CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema...
Phase 4
Atlanta, Georgia, United States and 29 other locations
This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 52 weeks by subjects with atopic dermatitis (eczema)....
Phase 3
Sandy Springs, Georgia, United States and 91 other locations
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...
Phase 3
Sandy Springs, Georgia, United States and 41 other locations
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...
Phase 3
Sandy Springs, Georgia, United States and 47 other locations
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...
Phase 2
Sandy Springs, Georgia, United States and 39 other locations
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Phase 2
Atlanta, Georgia, United States and 77 other locations
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...
Phase 3
Sandy Springs, Georgia, United States and 83 other locations
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...
Phase 3
Marietta, Georgia, United States and 105 other locations
Global Assessment for Atopic Dermatitis (vIGA-AD).Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Eczema...
Phase 3
Sandy Springs, Georgia, United States and 196 other locations
, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....
Phase 3
Atlanta, Georgia, United States and 234 other locations
Clinical trials
Research sites
Resources
Legal